Preclinical and clinical evidence demonstrates strains in DS-01® support tight junction integrity and healthy bacterial toxin (LPS) exclusion in the digestive tract.*

Our methodology for selecting strains gives DS-01® maximum efficacy across a broad range of existing microbiomes and their networks. Our microbial genomics capabilities allow us to map every microbial gene in DS-01® with unprecedented depth and clarity (100MM base pair depth reads). With 24 distinct strains, representing 12 species, DS-01® contains significantly more unique (non-redundant) and total (redundant) microbial genes compared to other probiotics, providing high versatility, and functionality to deliver broad-spectrum benefits to your patients.

DS-01® stands on a foundation of rigorous scientific validation, with 10 clinical trials and 14 pre-clinical trials underpinning our strain-specific benefits. We have also completed three additional double-blind, randomized, placebo-controlled trials on DS-01®, including one under an investigational new drug (IND) application. Our research protocols and endpoints are designed with leading scientific and medical key opinion leaders.*

Based on three double-blind, randomized, placebo-controlled trials, DS-01® has no serious adverse effects and is efficacious for supporting gastrointestinal health through ease of evacuation, bloating, gas production, abdominal pain, serotonin production, and the recovery of low-abundance species during and after a course of broad-spectrum antibiotics. DS-01® has published data supporting delivery at 100% potency of the declared probiotic species (53.6 billion AFU) through the entire gastrointestinal system, with a complete release in the small intestine, under both fed and fasted conditions.*